Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer

Pfizer

Status: Completed

Conditions: Breast Neoplasm

Treatments: Drug: Epirubicin: Observational Study

Study type: Observational

Funder types: Industry

Identifiers

NCT01061359

378-ONC-0030-0144

A6051029/MOI99056

Details and patient eligibility

About

Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events.

(E=Epirubicin; C =Cyclophosphamide)

Full description

Postmarketing surveillance study. Non-Probability Sample

Enrollment: 1,981 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pre- and postmenopausal female patients with histologically confirmed primary breast cancer

Exclusion criteria

• Metastatic breast cancer, locally advanced or recurrent breast cancer, previous cancer history

Trial design

1,981 participants in 1 patient group

Non-Interventional Study

Description:

Chemotherapy containing Epirubicin

Treatment:

Drug: Epirubicin: Observational Study